Immunacia's Genetic Immunity Presents DermaVir at the 7th International Conference on Nanosciences & Nanotechnologies – A Unique Nanomedicine for Therapeutic HIV Vaccine  
7/12/2010 8:33:49 AM

BUDAPEST, Hungary & MCLEAN, Va.--(BUSINESS WIRE)--Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week’s 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field. Dr. Lisziewicz has been invited to present the Company’s development of DermaVir, the first nanomedicine-based therapeutic vaccine for HIV/AIDS, on Tuesday, July 13th.